Expert panel issues long-term practice guidance for GLP-1 therapy in obesity

The wire

1. 01A board of obesity and metabolic disease clinicians published consensus recommendations on sustained GLP-1 receptor agonist use, covering baseline phenotyping, treat-to-benefit targets, maintenance therapy and adverse event management.
2. 02Prescribers and telehealth operators get a framework for what happens after initial weight loss, including dose flexibility, adherence support and economic sustainability barriers.
3. 03These are expert opinion recommendations rather than trial-derived guidelines; the authors say future real-world data initiatives are needed to refine them.

From the source

Long-term GLP-1 receptor agonist therapy in obesity: expert panel recommendations for good clinical practice

Frontiers in endocrinology · 2026 · Brancato D, Borretta G, Chianelli M et al.